NOVO-B:CPH
Novo Nordisk A/S
259,60 DKK
arrow_downward
-1,46%(-3,85) 1K
16-okt, 17:00:00 (GMT+2) · DKK
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoNOVO-B tikeri uchun statistika yaratilmoqda...
Ochish
261,00 DKK
Yuqori
262,15 DKK
Past
259,35 DKK
Bozor kapitali
870,08 mlrd
Oʻrtacha hajm
5,23 mln
Hajmi
5,27 mln
52 haftalik eng yuqori
409,95 DKK
52 haftalik eng past
224,25 DKK
Muomaladagi aksiyalar
3,39 mlrd
Xodimlar soni
67 ming
Ochish
261,00 DKK
Yuqori
262,15 DKK
Past
259,35 DKK
Bozor kapitali
870,08 mlrd
Oʻrtacha hajm
5,23 mln
Hajmi
5,27 mln
52 haftalik eng yuqori
409,95 DKK
52 haftalik eng past
224,25 DKK
Muomaladagi aksiyalar
3,39 mlrd
Xodimlar soni
67 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
The Motley Fool
·
5 soat oldin
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
Yahoo Finance
·
6 soat oldin
Novo Nordisk’s Growth Story Is Under Pressure as Eli Lilly Gains Ground
ad-hoc-news.de
·
6 soat oldin
Novo-Nordisk stock: Citi cuts target for Novo-Nordisk stock to DKK 296
Traders Union
·
13 soat oldin
Novo Nordisk shares technical analysis: Buyer support underpins upward price move
Profil
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
Novo Nordisk A/S haqida
CEOMaziar Mike Doustdar
Xodimlar soni66,7 ming
Asos solingan1923
Bosh ofislarBagsværd, Capital Region of Denmark, Daniya
Sektor-
Veb-saytnovonordisk.com